Jonathan Kaufman, MD

@TMSchmidtMD @WinshipAtEmory On the way to your h score of 100

I'm a little awestruck at the sight of my fellowship research project hitting the 100 citation mark! What an amazing and timely project that was designed for me by @JKaufmanMD, Larry Boise, and @WinshipAtEmory myeloma group. Couldn't have done it without such great mentors!

⁦@WinshipAtEmory⁩ ⁦@SagarLonialMD⁩ ⁦@JKaufmanMD⁩ the honor to have a drink from that king glass at Sagar home happens when you hit an important career mile stone. Congratulations my friend - you are an associate professor

An even DOZEN! Jan 27, 2024 - my 12th stem cell birthday. Couldn’t think of a better way to celebrate than to enjoy breakfast with the nurses and team on the transplant floor. I would not be here without them. @WinshipAtEmory @SagarLonialMD @JKaufmanMD @theMMRF @KathyGiusti

@Dr_AmerZeidan Yes. No.

If U have any doubt why CROs shouldn’t be doing clinical research; just read from a CRO monitor: “Subject x was expected to get aza for 7 days consecutively but D7 was given on D8 bc D7 was thanksgiving day. Plz verify U understand dosing & whether immediate reporting is needed”

Excited to share our experience with prophylactic tocilizumab for prevention of teclistamab associated CRS! @EMarinPA_C ⁦@BloodCancerJnl⁩ nature.com/articles/s4140…

@Bethfaiman @RahulBanerjeeMD @MMKingT VRD did not underperform (see Griffin and our presentation of RVd vs D RVD). Look at the supplement, they have an incredibly high % of planned doses delivered in both arms. But the apparent/possible lack of benefit in the 65 and older is likely due to this dosing.

@RahulBanerjeeMD Could it be that VRD group underperformed as the dosing of the comparator arm seemed extreme? We know pts do not tolerate #dex and especially in high doses. The dexamethasone dose was 40 mg d 1-4, 9-12 and the V was d1,4, 8 and 11? @MMKingT

#MMsm PERSEUS used a mirror reflection to 🤺 Medusa, and we should reflect on how amazing it feels to dethrone VRd triplets in myeloma. Also to see MRD reported at 10^-6 in an NEJM paper! Another reflection of how far we've come as a field 👏 Congrats to all investigators!

@bdermanmd You only need to learn this lesson once. Hopefully a near miss.

One of those days...

Looking for an intimate learning experience? ASH is bringing small-meeting networking and the most influential #ASH23 research to you! Registration is now open for North America and Asia-Pacific meetings. Details: loom.ly/vZaw4fg 🧵 for Asia-Pacific dates

Bendamustine va Fludarabine/cyclophosphamide as lymphodepletion prior to BCMA CAR-T in myeloma #mmsm #cartsm Our two center experience @JanakiramMurali nature.com/articles/s4140…

@RahulBanerjeeMD @szusmani @bdermanmd @rajshekharucms @GKaurMD @UrviShahMD @EagleMyeloma @MyelomaSLC As I am a Luddite, I have no smart phrases. But if I did, I would include @NBahlis JCO paper of Ven Dara.

Adding @szusmani @bdermanmd @rajshekharucms @GKaurMD @UrviShahMD @JKaufmanMD @EagleMyeloma @MyelomaSLC and others whom I've discussed this with in the last week in person or on the Internet!

Last week, I learned not to count my CANOVAs before they hatch... This week, I updated my Epic dotphrases for t(11;14) #MMsm or amyloidosis - I add "rationale for ven" as separate problem so it's in my note without cluttering plan. I'd love feedback and/or happy to send text!

Brilliant analysis by @Rfonsi1 This is the key point. Without an approval, we are not able to do these studies.

Excited to share the most recent work from the Dhodapkar Lab. Nancy Villa and I collaborated with the whole lab to make intriguing discoveries re: immune infiltration in MM and its precursor, MGUS. doi.org/10.1172/JCI167….🧵

Big news in the #amyloidosis world with the release of top line results for the Phase 3 #acoramidis trial, ATTRIBUTE-CM. Main message: It worked! 🍾 A lot of fascinating history behind this story. What else can we learn from the data? Details to follow… (1/14)

Emory group does it again! Important @JCOOP_ASCO #MMsm research: Black race an in independent predictor of bortezomib-related neuropathy (46% vs 34%) despite similar sex, DM, etc. Important to take symptoms seriously, dose reduce prn, and eschew twice-weekly Velcade! @katmapes

I’m excited to co-chair the upcoming Innovations in Cancer Care Summit alongside @JKaufmanMD and the rest of our @WinshipAtEmory Faculty as part of the @AJMC_Journal Institute of Value Based Medicine Join us in person July 25th as our faculty experts discuss some of the most pertinent topics in Hematology and Oncology such as: ◼️Precision Medicine in Lung Cancer ◼️Targeted therapies in CLL ◼️The role of Antibody Drug Conjugates in Bladder Cancer ◼️HR+/HER 2 - Breast Cancer Treatments ◼️Panel Discussion on Driving Innovation In Patient Care I’m excited about this event and hope to see everyone there!

The serum free light chain FLC assay. Tutorial. #MedTwitter #MyelomaVR Frequently ordered and frequently abnormal. This thread will reduce unnecessary headaches and referrals. 1/ Don’t order it unless you are suspecting myeloma, amyloid or related disorder

Then and NowHarnessing Immunity in Myeloma: Wine That Keeps Getting Better? ashpublications.org/thehematologis…

@RahulBanerjeeMD I think the TEC/Tal data argues against T cell exhaustion.

My hot take: while BCMA loss can certainly drive late teclistamab failures, I bet T-cell exhaustion drives early PD. Rationale: After 3 cycles of tec in MajesTEC-1, sBCMA levels (shed by #MMsm cells) quintupled in SD/PD: perhaps γ secretase, but my bet is ⬆️BCMA on⬆️ MM cells.

Great to see excellent presentation from the new generation of #mmsm stars at #IMWGsummit23! Dr. Nisha Joseph @WinshipAtEmory presents on strategies for newly diagnosed myeloma. Benefit for Dara in 1L more clear. What about carfilzomib vs velcade combo in high risk?

@TomBmt133 Well deserved! Congratulations

What an honor to be recognized - Brian has been an amazing mentor and such an advocate for patients. Truly humbled